6446 Stock Overview
A biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 6/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
PharmaEssentia Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$767.00 |
52 Week High | NT$788.00 |
52 Week Low | NT$281.00 |
Beta | 0.56 |
1 Month Change | 6.97% |
3 Month Change | 29.78% |
1 Year Change | 143.49% |
3 Year Change | 147.02% |
5 Year Change | 630.48% |
Change since IPO | 265.60% |
Recent News & Updates
Recent updates
PharmaEssentia Corporation (TWSE:6446) Stock Rockets 25% But Many Are Still Ignoring The Company
Jan 08Does PharmaEssentia (TWSE:6446) Have A Healthy Balance Sheet?
Dec 18We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings
Aug 20PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues
Jul 02PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues
Jul 02Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?
Apr 02Shareholder Returns
6446 | TW Biotechs | TW Market | |
---|---|---|---|
7D | 9.7% | 4.0% | 0.4% |
1Y | 143.5% | 21.6% | 23.1% |
Return vs Industry: 6446 exceeded the TW Biotechs industry which returned 21.6% over the past year.
Return vs Market: 6446 exceeded the TW Market which returned 23.1% over the past year.
Price Volatility
6446 volatility | |
---|---|
6446 Average Weekly Movement | 6.2% |
Biotechs Industry Average Movement | 5.3% |
Market Average Movement | 4.5% |
10% most volatile stocks in TW Market | 8.0% |
10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6446's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6446's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | n/a | Ko-Chung Lin | www.pharmaessentia.com |
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia.
PharmaEssentia Corporation Fundamentals Summary
6446 fundamental statistics | |
---|---|
Market cap | NT$255.32b |
Earnings (TTM) | NT$1.85b |
Revenue (TTM) | NT$8.32b |
138.3x
P/E Ratio30.7x
P/S RatioIs 6446 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6446 income statement (TTM) | |
---|---|
Revenue | NT$8.32b |
Cost of Revenue | NT$1.07b |
Gross Profit | NT$7.25b |
Other Expenses | NT$5.40b |
Earnings | NT$1.85b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 5.54 |
Gross Margin | 87.10% |
Net Profit Margin | 22.19% |
Debt/Equity Ratio | 0.3% |
How did 6446 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/14 23:14 |
End of Day Share Price | 2025/02/14 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PharmaEssentia Corporation is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
null null | Capital Securities Corporation |
Jianzheng Wu | Capital Securities Corporation |
Wangbin Zhou | Citigroup Inc |